Principal Scientist, Translational Computational Biology

Bristol-Myers Squibb Co; United States; On-site; USD 150,000 - 230,000; Full time

Job summary

Bristol Myers Squibb is seeking a Principal Scientist, Translational Computational Biology to serve as the computational partner to our oncology drug development programs across discovery, translational research, and early clinical development.

You will translate patient-derived molecular, spatial, and clinical data into biomarker hypotheses, patient stratification strategies, indication prioritization, pharmacodynamic readouts, and decision-grade recommendations, applying AI-enabled

Responsibilities

• Oncology drug development program, translational, and early clinical development support
• Oncology program partnership
• Serve as the translational computational scientist for assigned oncology drug development programs across the discovery-to-early-clinical continuum, from target validation through early clinical studies
• Biomarker

Job description

At Bristol Myers Squibb, our employees often ask, "Who are you working for?"—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. When you join BMS, you are joining a high-achieving team united by a common mission.

Here, you’ll get the chance to grow and thrive through opportunities that are uncommon in scale and scope. You’ll pursue innovative ideas while advancing professionally alongside some of the brightest minds in biopharma.

The Oncology Translational IPS team is seeking a Principal Scientist, Translational Computational Biology, to serve as the computational partner to our oncology drug development programs across discovery, translational research, and early clinical development. You will translate patient-derived molecular, spatial, and clinical data into biomarker hypotheses, patient stratification strategies, indication prioritization, pharmacodynamic readouts, and decision‑grade recommendations. The majority of the role is embedded with oncology drug development programs and clinical development teams. The remainder builds computational capability for the broader portfolio: spatial biology, AI‑enabled translational science, and reusable analytical methods. The exact emphasis of that capability work will evolve with portfolio priorities and emerging technologies. This role is for someone who understands drug development, not only data analysis. We are looking for a scientist with a working understanding of the path from target validation and candidate selection through IND‑enabling work and early clinical studies (including dose escalation and expansion), and of the strategic role biomarkers play at each stage, who can carry an interpretation into the forum where the decision is actually made.

What you will have to work with Spatial transcriptomics and spatial proteomics / multiplex immunofluorescence. Dedicated analytical ownership across multiple concurrent oncology programs, on the platforms the team runs today: Xenium, Visium, and Visium HD for spatial transcriptomics, and platforms such as COMET or PhenoCycler for spatial proteomics / multiplex immunofluorescence. Backed by a pan‑cancer spatial atlas license, an H&E‑to‑mIF platform partnership, and cloud compute alongside a translational informatics team that builds its own methods. These platforms are already funded and running; this role exists to realize their scientific value. Clinical and multi‑modal patient‑derived datasets from BMS's industry‑leading early‑stage clinical studies in oncology: the molecular and clinical biomarker data generated by our own early‑phase trials, spanning RNA‑seq, ctDNA, WES, TCR‑seq, and CTC, together with flow cytometry, cytokine profiling, IHC, and proteomics. Your contributions will influence development strategies and play a vital role in propelling the BMS early‑stage oncology pipeline forward, directly impacting the treatment of cancer patients. You will apply these data across two areas: Oncology drug development program, translational, and early clinical development support. The majority of the role. Biomarker strategy; patient selection and stratification; indication prioritization; target validation; IND‑enabling and early clinical trial interpretation; data‑driven recommendations for program decisions. Computational innovation and portfolio capability. The remainder. Spatial biology; AI‑enabled translational science; multimodal integration; reusable workflows, automation, and scalable analytical methods that serve the portfolio rather than a single program.

Key Responsibilities

• Oncology drug development program, translational, and early clinical development support
• Oncology program partnership.
• Serve as the translational computational scientist for assigned oncology drug development programs across the discovery‑to‑early‑clinical continuum, from target validation through early clinical studies.
• Biomarker